Surims Ltd Logo
 
 
 
 
 
 
Lonza Group Logo  
 
 
Premium+ Profile
 
If you'd like to claim this company profile for Lonza Group, please Contact Us.
 

Lonza Group News

The latest news, announcements and press releases from Lonza Group.

 
 
03
May
2021
03rd May 2021
 

Lonza and Moderna Enter to Double Drug Substance Production for COVID-19 Vaccine in Visp


  • New agreement for three further production lines at Lonza’s site in Visp, Switzerland

  • Additional production lines will come online sequentially

  • All three are expected to be operational in the earlier part of 2022


Basel, Switzerland, 29 April 2021 – Lonza today announced the expansion of its collaboration with Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, to manufacture the drug substance for the COVID-19 Vaccine Moderna.


The expanded collaboration provides for the installation of three additional drug substance manufacturing lines at Lonza’s Visp (CH) site. This will double the existing drug substance production for COVID-19 Vaccine Moderna at the site.


In May 2020, Lonza and Moderna announced a 10-year strategic collaboration agreement to enable the manufacture of Moderna’s COVID-19 vaccine and additional Moderna products in the future. Since then, Lonza has installed three production lines at its Visp (CH) site and one further production line in Portsmouth (US). Production in Visp (CH) commenced within eight months of the initial agreement.

 
Read the full story »
 
 
03
April
2021
03rd April 2021
 

Lonza Completes Divestment of Sites to NextPharma

“The strategic divestment of our Ploermel and Edinburgh sites will enable NextPharma to benefit from operational synergies and optimize existing expertise and technologies. In this context, as we close the divestment process, we are confident that NextPharma is well placed to develop and grow both sites to their full potential. We wish to thank the leadership teams and employees at the Ploermel and Edinburgh sites for their continuing dedication and professionalism during the transition period.”

 
Read the full story »
 
 
03
December
2020
03rd December 2020
 

Lonza Announces Customer-Dedicated Suites for Commercialization of Bioconjugates

Basel, Switzerland, 2 December 2020 – Lonza today announced a long-term, strategic collaboration for bioconjugation with a global biopharma company. Under the terms of the agreement, Lonza will construct two new customer-dedicated conjugation suites for the commercialization of antibody-drug conjugates (ADCs) at its Visp (CH) site.


As part of Lonza’s Ibex® Dedicate model, a technology-agnostic supply solution that helps reduce time to market and control investment risk, two bioconjugation suites totaling 1500m2 of active manufacturing space will be built out within a pre-existing shell. The new suites will also benefit from established quality control (QC) labs, logistics and other central services, allowing for faster ramp-up times, assured delivery and high performance.


The high throughput bioconjugation suites will be capable of handling highly-potent materials for cancer therapies and will initially manufacture two therapies. The new dedicated facility will employ around 200 staff, with operations expected to start from the end of 2022.


ADC’s are bioconjugates and represent an innovative therapeutic modality that is growing rapidly and providing effective therapies to patients with reduced side effects. ADC’s usually combine an antibody with a highly-potent payload (via a linker molecule) to target cancer cells. The antibody serves as the delivery method to target the toxic drug precisely to cancer cells, limiting toxicity to healthy cells.


Lonza has developed the specific expertise and technology to de-risk the development and manufacturing of bioconjugates and now supports the majority of commercially approved ADCs. In addition, Lonza also offers all elements of a complex supply chain, including manufacturing of biomolecule, synthetic payload, linker and subsequent conjugation at a single site.

 
 
30
November
2020
30th November 2020
 

Lonza Expands Highly Potent Drug Product Development and Manufacturing Capabilities

Tampa, USA, 18 November 2020 – Lonza has announced additional investments in its oral drug product development and manufacturing capabilities at its Tampa FL site. Capability for formulation development has been enhanced with the upgrade of drug product development laboratories for highly potent material handling. Dry granulation processing has been expanded and standardized with the addition of Gerteis roller compaction equipment. The new roller compactor will be equipped with high containment and adds to Lonza’s integrated highly potent API (HPAPI) value chain across drug substance, particle engineering and specialized drug product.


The containment capability of the new roller compaction unit complements Lonza’s leading capabilities in HPAPI processing across its site network in the US and Europe. The Visp, Switzerland site has one of the world’s largest capacity for HPAPI development and manufacturing. Contained particle engineering, using either jet milling or spray dry processing, and specialized oral solid or parenteral drug product capabilities are also available within the network.


Lonza has invested more than $15M to expand and upgrade the Tampa site capabilities over the last two years. The new roller compaction equipment complements previously made HPAPI processing investments inclusive of a new sampling and dispensing suite, a dedicated suite for product development, and two new product manufacturing suites.

 
Read the full story »
 
 
03
November
2020
03rd November 2020
 

Lonza Announces Agreement to Manufacture AstraZeneca's COVID-19 Long-Acting Antibody Combination

The agreement will provide capacity for the manufacturing of AZD7442, currently being developed for the potential prevention and treatment of COVID-19





  • cGMP manufacturing of the two long-acting antibodies to begin in H1 2021 at Lonza's Portsmouth, NH (USA) site


Quote from Jean-Christophe Hyvert, Chief Commercial Officer, Lonza:


"Given the threats posed from the ongoing COVID-19 pandemic, advancing options for prevention and treatment are of crucial importance. Our team is extremely motivated to welcome AstraZeneca as one of the first projects in our new mid-scale facility in Portsmouth, NH. The new facility will provide AstraZeneca with the flexibility and the speed needed to manufacture AZD7442 on accelerated timelines."


Basel, Switzerland, 30 October 2020 – Lonza announced today that the company has signed an agreement with AstraZeneca to manufacture AZD7442, a combination of two long-acting antibodies (LAABs) for the potential prevention and treatment of COVID-19. AZD7442 is currently in Phase I clinical studies and AstraZeneca plans to advance the LAAB combination into Phase 3 trials in the coming weeks.


The agreement enables AstraZeneca to leverage Lonza's extensive antibody manufacturing expertise, as well as QC testing, regulatory competence, and experience with accelerated manufacturing campaigns.


Under the terms of the agreement, Lonza will manufacture drug substance (DS) for AZD7442 at Lonza's facilities in Portsmouth (US).  Operations are expected to start in H1 2021.


AstraZeneca will be one of the first companies to access Lonza's new mid-scale facilities in Portsmouth, NH (USA). With operations starting later this year, the new hybrid facility combines the cost efficiencies of mid-scale stainless steel bioreactors with disposable downstream technology for flexibility and speed. Automation and process analytic technology also open up the possibilities for real-time data sharing and transparency.



 
Read the full story »
 
 
23
October
2020
23rd October 2020
 

Lonza Expands Its Capsule Manufacturing Capacity


  • Investment of CHF85m will expand capsule manufacturing capacity by 30 billion capsules annually

  • The new expansion involves eight global Lonza sites

  • The investment aims to address the increasing global demand for capsules

 
Read the full story »
 
 
24
August
2020
24th August 2020
 

Lonza Expands Microbial Capacity to support Servier


  • New mid-scale microbial facility to support Servier with active pharmaceutical ingredient (API) for acute lymphoblastic leukemia (ALL) therapies

  • Sixth facility to be housed in Lonza’s new biopark in Visp, Switzerland, currently under construction

  • Operational in the second half of 2022, 100 new staff to be recruited

 
Read the full story »
 
 
10
April
2019
10th April 2019
 

Lonza and Chr. Hansen in Joint Venture to Accelerate Momentum in Microbiome

Copenhagen (DK) and Basel (CH), 2 April 2019 – Chr. Hansen Holding A/S, a leading global bioscience company, and Lonza AG, a leading pharma contract manufacturing company, have signed an agreement to establish a 50/50 joint venture to pioneer the live biotherapeutic products (LBPs) industry and position themselves as the leading contract development and manufacturing partner (CDMO) for biotech and pharma customers. The joint venture will be a 50/50 controlled legal entity that will operate from its headquarters in Basel (CH) and have production facilities in Denmark and Switzerland.

 
Read the full story »
 
 
18
February
2019
18th February 2019
 

Emerald Health Pharmaceuticals and Lonza Announce Agreement for Manufacturing of Novel Cannabinoid-Derived Drug Candidate

San Diego, CA (USA) and Basel (CH) 13 February 2019 – Emerald Health Pharmaceuticals and Lonza have announced an agreement for the large-scale manufacturing of a new synthetic derivative of cannabidiol (CBD) and its oral drug product for the treatment of multiple sclerosis (MS) and systemic scleroderma, also known as systemic sclerosis (SSc). Under the terms of the agreement, Lonza Pharma & Biotech will synthesize the active pharmaceutical ingredient (API) / drug substance (VCE-004.8) and develop the drug product (EHP-101) as liquid-filled capsules.

 
Read the full story »
 
 
18
January
2019
18th January 2019
 

Lonza Collaborates with Takeda to Bring Cancer Treatment to Patients

Basel, Switzerland, 11 January 2019 – Lonza today announced another major milestone in its multiproduct partnership with Takeda. Takeda Pharmaceutical Company Limited announced in November 2018 that the European Commission (EC) granted marketing authorization for ALUNBRIG (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NLSC) previously treated with crizotinib.

 
Read the full story »
 
 
21
July
2017
21st July 2017
 

Lonza Completes Acquisition of Capsugel to Create Leading Integrated Solutions Provider

Acquisition aligns closely with Lonza’s strategy to accelerate Lonza’s growth and ability to deliver value along the healthcare continuum. Transaction price of USD 5.5 billion, including refinancing of existing Capsugel debt of approximately USD 2 billion.
 
Read the full story »
 
 
10
January
2017
10th January 2017
 

Lonza to buy Capsugel for $5.5bn, no site divestitures planned

Lonza has agreed to buy US capsule manufacturer Capsugel for $5.5bn (€5.2bn) in cash in an acquisition the Swiss firm says will expand its drug delivery business and enable savings of CHF100m a year by 2019.
 
Read the full story »
 
 
30
December
2016
30th December 2016
 

Lonza says it is negotiating deal to buy Capsugel

Swiss CMO Lonza, which has been searching for a game-changing M&A deal—having let Catalent get away—may have found one in contractor Capsugel.
 
Read the full story »
 
 
04
November
2016
04th November 2016
 

Lonza opens formulation development and testing lab

Lonza has opened a drug quality testing and formulation laboratory in Basel, Switzerland.
 
Read the full story »
 
 
21
July
2016
21st July 2016
 

Lonza Reports Best First Half in History with Continued Strong Momentum

20% CORE EBIT growth and 6% sales growth
 
Read the full story »
 
 
15
January
2016
15th January 2016
 

Lonza Reports Strong Sales and Profit Growth in 2015

• Strong sales growth in reported currency of 4.5% (a growth of 5.7% in constant exchange rates) resulted in sales of CHF 3.80 billion.
 
Read the full story »
 
 
23
January
2014
23rd January 2014
 

Lonza Delivers Strong Results Following Continuing Success of Transformation Efforts----

Lonza Delivers Strong Results for 2013
 
Read the full story »
 
 
 

Claim This Profile

This is the News section of the company profile page for Lonza Group on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.

 
 
Lonza Group company details, activities, contacts and reviews.
 
Lonza Group documents, images and videos.
 
Lonza Group partnership and licensing opportunities.
 
Lonza Group latest news, announcements and press releases.
 
Lonza Group global factories, offices and locations.
 
Lonza Group legal and financial information.
 
 
 
 
 
 
 

About Us

Surims Ltd is a consultancy established in 2003 supporting companies in the identification, qualification and management of quality vendors and suppliers in ingredients and formulations.

The Pharmaceutical Services Directory supports the identification and on-boarding of quality suppliers and also incorporates software features that manage relationships between suppliers and their customers. These include the building and deployment of questionnaires and assessments, electronic signatures and sign-offs and project management between vendor/partner and customer.

Access to the features and software is available on a 'pay as you go' basis, or a customised version can be licensed for your company for its own on-boarding and supplier management activities. Further information on our software services can be found at https://www.surims.com.

 
 
 

Get in Touch

The Pharmaceutical Services Directory
info@pharmaservicesdirectory.com

 
 

© 2021 Surims Ltd | All Rights Reserved.